SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in <i>db/db</i> Mice, a Model of Type 2 Diabetes

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in <i>db/db</i> Mice, a Model of Type 2 Diabetes

Recent data have indicated the emerging role of glomerular autophagy in diabetic kidney disease. We aimed to assess the effect of the SGLT2 inhibitor empagliflozin, the DPP4 inhibitor linagliptin, and their combination, on glomerular autophagy in a model of type 2 diabetes. Eight-week-old male <i...

Full description

Bibliographic Details
Main Authors:	Anton I. Korbut, Iuliia S. Taskaeva, Nataliya P. Bgatova, Natalia A. Muraleva, Nikolai B. Orlov, Maksim V. Dashkin, Anna S. Khotskina, Evgenii L. Zavyalov, Vladimir I. Konenkov, Thomas Klein, Vadim V. Klimontov
Format:	Article
Language:	English
Published:	MDPI AG 2020-04-01
Series:	International Journal of Molecular Sciences
Subjects:	autophagy, podocyte, type 2 diabetes, diabetic nephropathy, empagliflozin, linagliptin
Online Access:	https://www.mdpi.com/1422-0067/21/8/2987

Similar Items

Simultaneous quantification of empagliflozin, linagliptin and metformin hydrochloride in bulk and synthetic mixture by RP–LC method
by: Ishita M. Patel, et al.
Published: (2021-08-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
by: Francesca Iannantuoni, et al.
Published: (2019-11-01)

Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin
by: Ömercan Topaloğlu, et al.
Published: (2019-03-01)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
by: Soulmaz Fazeli Farsani, et al.
Published: (2019-09-01)

Renal insufficiency and linagliptin therapy: a case report
by: Anna Corsi, et al.
Published: (2018-09-01)

The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway
by: Yang Zhou, et al.
Published: (2017-05-01)

Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin
by: Yiwen Huang, et al.
Published: (2016-08-01)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
by: Chenguang Li, et al.
Published: (2019-02-01)

Linagliptin in the frail elderly diabetic patient
by: Eva Palmieri
Published: (2018-09-01)

Comparison of Therapeutic Effects of Linagliptin and Metformin in Patients with Type 2 Diabetes: A systematic Review and Meta-Analysis
by: Hamidreza Dehghan, et al.
Published: (2018-04-01)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
by: Woodman OL, et al.
Published: (2019-08-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study)
by: Luis M. Pérez-Belmonte, et al.
Published: (2018-09-01)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
by: Guntram Schernthaner, et al.
Published: (2019-06-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Combination treatment for type 2 diabetes mellitus (T2DM) : dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin
by: Erna Kristin
Published: (2017-10-01)

SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction
by: Ahmed S. Ahmed, et al.
Published: (2021-07-01)

A facile nano-iron oxide sensor for the electrochemical detection of the anti-diabetic drug linagliptin in the presence of glucose and metformin
by: Manal A. El-Shal, et al.
Published: (2019-06-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019-04-01)

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)

A new challenge for linagliptin: diabetes, organ transplantation and chronic renal insufficiency in the same patient
by: Benedetta M. Bonora
Published: (2018-09-01)

Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes
by: Stephanie A. Eid, et al.
Published: (2020-10-01)

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
by: Debmalya Sanyal, et al.
Published: (2013-01-01)

Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation
by: Wang H, et al.
Published: (2020-09-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
by: Hiroyuki Takahashi, et al.
Published: (2019-07-01)

Post-marketing Study of Linagliptin: A Pilot Study
by: Gabrielle Kéfrem Alves Gomes, et al.
Published: (2019-05-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
by: Takashi Kadowaki, et al.
Published: (2019-05-01)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014-10-01)

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
by: Kedia R, et al.
Published: (2016-09-01)

Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
by: Luis M. Pérez-Belmonte, et al.
Published: (2021-08-01)

A Localized Painful Rash Induced by Linagliptin in a Patient with type 2 Diabetes
by: İsmail Yıldız, et al.
Published: (2019-05-01)